Cargando…

Primary care‐based screening for cardiovascular risk factors in patients with psoriasis

BACKGROUND: Studies assessing cardiovascular disease (CVD) risk factors in patients with psoriasis have been limited by selection bias, inappropriate controls or a reliance on data collected for clinical reasons. OBJECTIVES: To investigate whether screening for CVD risk factors in patients with psor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rutter, M.K., Kane, K., Lunt, M., Cordingley, L., Littlewood, A., Young, H.S., Chew‐Graham, C.A., Hilton, R., Symmons, D.P.M., Griffiths, C.E.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113692/ https://www.ncbi.nlm.nih.gov/pubmed/26990294 http://dx.doi.org/10.1111/bjd.14557

Ejemplares similares

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
por: Rungapiromnan, W., et al.
Publicado: (2019)

‘I should have taken that further’ – missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed‐methods study
por: Nelson, Pauline A., et al.
Publicado: (2015)

What are the barriers to physical activity in patients with chronic plaque psoriasis?
por: Auker, L., et al.
Publicado: (2020)

‘New to me’: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well(®) patient materials mixed‐methods feasibility study
por: Nelson, P.A., et al.
Publicado: (2017)

Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis
por: Thorneloe, R.J., et al.
Publicado: (2016)

Physical activity is important for cardiovascular health and cardiorespiratory fitness in patients with psoriasis
por: Auker, L., et al.
Publicado: (2021)

‘On the surface’: a qualitative study of GPs’ and patients’ perspectives on psoriasis
por: Nelson, Pauline A, et al.
Publicado: (2013)

Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis
por: Iskandar, I.Y.K., et al.
Publicado: (2017)

‘Mind the gap’: what patients and clinicians believe is ‘unknown’ about psoriasis
por: Majeed‐Ariss, R., et al.
Publicado: (2020)

Self-reported pain severity is associated with a history of coronary heart disease
por: Parsons, S, et al.
Publicado: (2015)

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy
por: Yiu, Z.Z.N., et al.
Publicado: (2019)

Implementation of the PsoWell™ Model for the Management of People with Complex Psoriasis
por: HEWITT, Rachael M., et al.
Publicado: (2021)

Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength
por: Thorneloe, Rachael J., et al.
Publicado: (2018)

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis
por: Yiu, Z.Z.N., et al.
Publicado: (2019)

A rapid access clinic for psoriasis: first experiences
por: Reid, Claire, et al.
Publicado: (2022)

Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
por: Isaacs, JD, et al.
Publicado: (2005)

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials
por: Rungapiromnan, W., et al.
Publicado: (2017)

The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership
por: Majeed‐Ariss, R., et al.
Publicado: (2019)

Polymorphisms in the PTPN22 region are associated with psoriasis of early onset
por: Smith, RhLl, et al.
Publicado: (2008)

Do English healthcare settings use ‘Choice Architecture’ principles in promoting healthy lifestyles for people with psoriasis? An observational study
por: Keyworth, Chris, et al.
Publicado: (2015)

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Z.Z.N., et al.
Publicado: (2018)

The global state of psoriasis disease epidemiology: a workshop report
por: Griffiths, C.E.M., et al.
Publicado: (2017)

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population‐based cohort study
por: Springate, D.A., et al.
Publicado: (2016)

Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis
por: Franklin, Jarrod, et al.
Publicado: (2010)

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
por: Papp, K.A., et al.
Publicado: (2018)

Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials
por: Hampton, P., et al.
Publicado: (2021)

Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk
por: KLEYN, C. Elise, et al.
Publicado: (2020)

Concordance and timing in recording cancer events in primary care, hospital and mortality records for patients with and without psoriasis: A population-based cohort study
por: Trafford, Alex M., et al.
Publicado: (2021)

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study
por: Warren, R.B., et al.
Publicado: (2018)

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug
por: Hyrich, K. L., et al.
Publicado: (2008)

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register
por: Dixon, W G, et al.
Publicado: (2010)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

The Use of Screening Tools for Cardiovascular Risk Assessment in Psoriasis – A Case- Control Study
por: Neema, Shekhar, et al.
Publicado: (2022)

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
por: Mahil, S.K., et al.
Publicado: (2019)

Common and unique associated factors for medically unexplained chronic widespread pain and chronic fatigue()
por: McBeth, J., et al.
Publicado: (2015)

Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
por: Mason, K.J., et al.
Publicado: (2019)

Serious Infection Following Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis: Lessons From Interpreting Data From Observational Studies
por: Dixon, W G, et al.
Publicado: (2007)

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
por: Dixon, W G, et al.
Publicado: (2007)

CARDIOVASCULAR COMORBIDITIY IN PSORIASIS
por: Singh, Gurcharan, et al.
Publicado: (2011)

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
por: Dixon, W G, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_s9k3j2s4r8uj8efdcsng5s6mlg